Hellsten S, Månsson W, Henrikson H, Idwall I, Lindholm K, Mikulowski P, Mårtensson S, Oldbring J
Department of Urology, University of Lund, Sweden.
Scand J Urol Nephrol. 1990;24(1):35-8. doi: 10.3109/00365599009180357.
Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder. Initial complete response was obtained in 17 patients, 14 of whom remained without evidence of disease during follow-up averaging 28 months from cessation of mitomycin therapy. In three responding patients malignant cells reappeared in the urine during follow-up, although no recurrence of carcinoma could be proven in bladder biopsy specimens. In eight of the 17 non-responders, muscle invasion and/or metastatic disease developed during or after mitomycin treatment. The prostatic urethra was involved in five cases. Chemotherapy had to be discontinued because of chemical cystitis in three cases. Mitomycin C appears to be effective for intravesical treatment of carcinoma in situ of the urinary bladder. Close surveillance of these patients is mandatory, however, and must include monitoring not only of the bladder, but also of the prostatic urethra and the upper urinary tract.
对34例膀胱原位癌患者膀胱内给予丝裂霉素C，给药时间为2 - 32个月。17例患者获得初始完全缓解，其中14例在丝裂霉素治疗停止后平均28个月的随访期间无疾病证据。3例缓解患者在随访期间尿液中再次出现恶性细胞，尽管膀胱活检标本中未证实有癌复发。17例未缓解患者中有8例在丝裂霉素治疗期间或之后出现肌肉浸润和/或转移性疾病。5例累及前列腺尿道。3例因化学性膀胱炎而不得不停止化疗。丝裂霉素C似乎对膀胱原位癌的膀胱内治疗有效。然而，必须对这些患者进行密切监测，不仅要监测膀胱，还要监测前列腺尿道和上尿路。
